Salute e Benessere
IM Cannabis to Report Third Quarter 2024 Financial Results on Thursday, November 14th at 9:00am ET
If you are unable to join us live, a recording of the call will be available on our website at https://investors.imcannabis.com/ within 24 hours after the call.
Link for the to register for the zoom call: https://us02web.zoom.us/webinar/register/WN_1McuNcK_R62gmx7a3BplLg#/registration
IMC (Nasdaq: IMCC) (CSE: IMCC) is an international cannabis company that provides premium cannabis products to medical patients in
Israel and Germany , two of the largest medical cannabis markets. The Company has focused its resources to achieve sustainable and profitable growth in its highest value markets,
Israel and Germany . The Company leverages a transnational ecosystem powered by a unique data-driven approach and a globally sourced product supply chain. With an unwavering commitment to responsible growth and compliance with the strictest regulatory environments, the Company strives to amplify its commercial and brand power to become a global high-quality cannabis player.
The IMC ecosystem operates in Israel through Focus Medical Herbs Ltd., which imports and distributes cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs in Israel that enable the safe delivery and quality control of IMC products throughout the entire value chain. In Germany , the IMC ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients.
Company Contact:
Anna Taranko , Director Investor & Public Relations
IM Cannabis Corp.
+49 157 80554338
a.taranko@imcannabis.de
Oren Shuster , CEO
IM Cannabis Corp.
+972-77-3603504
info@imcannabis.com
View original content: https://www.prnewswire.co.uk/news-releases/im-cannabis-to-report-third-quarter-2024-financial-results-on-thursday-november-14th-at-900am-et-302297449.html